InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,610.00
(
0.00%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.45
(
-0.03%
)
Bitcoin
63,771.62
(
0.96%
)
Post# of 251732
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Double_Bagel

Send PM Follow Ignore
Followers 14
Posts 898
Boards Moderated 0
Alias Born 03/07/2011

Double_Bagel

Re: None

Monday, 11/24/2014 6:27:59 AM

Monday, November 24, 2014 6:27:59 AM

Post# of 251732
Deutsche Bank initiates Regulus Therapeutics $RGLS with Buy, Target $30

http://www.benzinga.com/news/14/11/5032141/deutsche-bank-initiates-coverage-on-regulus-therapeutics-at-buy-announces-30-00-p

There's a lot to like; platform, HCV, rare disease in 1 company.

Data in HCV patients for RG-101 was compelling after 1 dose, more importantly it provided first validation for platform

We see dramatic LT upside as this early platform story begins to play out

If both RG-101 and RG-012 were successful, our Regulus FV is $99/share
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up